? Has previously participated in this study.? Has previously received convalescent plasma with high level neutralizing anti-SARS-CoV-2antibodies (either in other study or in compassionate use program).? Known hypersensitivity to treatment with immunoglobulins (WHO grade 3-4).? Patient who has reached endpoint already at admission (direct adjunctive oxygen therapy inthe form of high-flow nasal oxygen (HFNO), mechanical ventilation or ICU admission for otherreason).

? Has previously participated in this study.? Has previously received convalescent plasma with high level neutralizing anti-SARS-CoV-2antibodies (either in other study or in compassionate use program).? Known hypersensitivity to treatment with immunoglobulins (WHO grade 3-4).? Patient who has reached endpoint already at admission (direct adjunctive oxygen therapy inthe form of high-flow nasal oxygen (HFNO), mechanical ventilation or ICU admission for otherreason).